MIM
INDV icon

MetLife Investment Management’s Indivior Pharmaceuticals INDV Stock Holding History

MetLife Investment Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
69,944
+2,385
+4% +$86.5K 0.01% 934
2026
Q1 		$2.06M Buy
67,559
+312
+0.5% +$10.3K 0.01% 1042
2025
Q4 		$2.41M Sell
67,247
-5,703
-8% -$174K 0.01% 983
2025
Q3 		$1.76M Hold
72,950
– – 0.01% 1149
2025
Q2 		$1.08M Buy
+72,950
New +$850K 0.01% 1267

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's INDV Position: Q2 2026 in Review

MetLife Investment Management increased its Indivior Pharmaceuticals (INDV) stake by 3.5% in Q2 2026, buying an estimated $86.5K and bringing the position to 69,944 shares worth $2.87M. The position accounts for 0.01% of the portfolio, ranked #934.

MetLife Investment Management first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • MetLife Investment Management held 69,944 shares of Indivior Pharmaceuticals worth $2.87M as of Q2 2026.
  • MetLife Investment Management bought 2,385 Indivior Pharmaceuticals shares in Q2 2026, an estimated $86.5K.
  • Indivior Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #934 holding.
  • MetLife Investment Management first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.